I agree that this site is using cookies. You can find further informations here.
X
LoRusso, Patricia
420  results:
Search for persons X
?
1

Pharmacokinetics (PK) of Tiragolumab in First‐in‐Human Stud..:

Garralda, Elena ; Oh, Do Youn ; Italiano, Antoine...
The Journal of Clinical Pharmacology.  64 (2024)  5 - p. 544-554 , 2024
Link: https://doi.org/10.1002/..
 
?
2

Circulating tumor DNA dynamics reveal KRAS G12C mutation he..:

Choi, Yoonha ; Dharia, Neekesh V. ; Jun, Tomi...
Clinical Cancer Research.  , 2024
Link: https://doi.org/10.1158/..
 
?
3

A crisis in clinical research:

Hong, David S ; LoRusso, Patricia ; Sznol, Mario
Journal for ImmunoTherapy of Cancer.  12 (2024)  7 - p. e008520 , 2024
Link: https://doi.org/10.1136/..
 
?
4

Entinostat, nivolumab and ipilimumab for women with advance..:

Roussos Torres, Evanthia.T. ; Ho, Won J. ; Danilova, Ludmila...
Nature Cancer.  5 (2024)  6 - p. 866-879 , 2024
Link: https://doi.org/10.1038/..
 
?
5

The HER2-directed antibody-drug conjugate DHES0815A in adva..:

Lewis, Gail D. ; Li, Guangmin ; Guo, Jun...
Nature Communications.  15 (2024)  1 - p. , 2024
Link: https://doi.org/10.1038/..
 
?
6

A Phase II Trial of the WEE1 Inhibitor Adavosertib in SETD2..:

Maldonado, Edward ; Rathmell, W. Kimryn ; Shapiro, Geoffrey I....
Cancer Research Communications.  , 2024
Link: https://doi.org/10.1158/..
 
?
7

Efficacy and Safety of the MDM2–p53 Antagonist Brigimadlin ..:

Yamamoto, Noboru ; Tolcher, Anthony ; Hafez, Navid...
OncoTargets and Therapy.  17 (2024)  - p. 267-280 , 2024
Link: https://doi.org/10.2147/..
 
?
8

The MDM2–p53 Antagonist Brigimadlin (BI 907828) in Patients..:

LoRusso, Patricia ; Yamamoto, Noboru ; Patel, Manish R....
Cancer Discovery.  13 (2023)  8 - p. 1802-1813 , 2023
Link: https://doi.org/10.1158/..
 
?
9

A pilot study of volumetric and density tumor analysis of A..:

Malarkey, Molly ; Toscano, Alex P. ; Bagheri, Mohammad Hadi...
Heliyon.  9 (2023)  8 - p. e18680 , 2023
Link: https://doi.org/10.1016/..
 
?
10

NCI 7977: A Phase I Dose-Escalation Study of Intermittent O..:

Cecchini, Michael ; Walther, Zenta ; Wei, Wei...
Cancer Research Communications.  3 (2023)  6 - p. 1113-1117 , 2023
Link: https://doi.org/10.1158/..
 
?
11

First-in-human study of oleclumab, a potent, selective anti..:

Bendell, Johanna ; LoRusso, Patricia ; Overman, Michael...
Cancer Immunology, Immunotherapy.  72 (2023)  7 - p. 2443-2458 , 2023
Link: https://doi.org/10.1007/..
 
?
12

Divarasib plus cetuximab in KRAS G12C-positive colorectal c..:

Desai, Jayesh ; Alonso, Guzman ; Kim, Se Hyun...
Nature Medicine.  30 (2023)  1 - p. 271-278 , 2023
Link: https://doi.org/10.1038/..
 
?
13

Multicenter Phase II Trial of the PARP Inhibitor Olaparib i..:

Fanucci, Kristina ; Pilat, Mary Jo ; Shyr, Derek...
Cancer Research Communications.  3 (2023)  2 - p. 192-201 , 2023
Link: https://doi.org/10.1158/..
 
?
14

A Phase I Dose-Escalation Study of LY3405105, a Covalent In..:

Garralda, Elena ; Schram, Alison M ; Bedard, Philippe L...
The Oncologist.  29 (2023)  1 - p. e131-e140 , 2023
Link: https://doi.org/10.1093/..
 
?
15

NCI10066: a Phase 1/2 study of olaparib in combination with..:

Cecchini, Michael ; Cleary, James M. ; Shyr, Yu...
British Journal of Cancer.  130 (2023)  3 - p. 476-482 , 2023
Link: https://doi.org/10.1038/..
 
1-15